{"id":"https://openalex.org/W4416626621","doi":"https://doi.org/10.1158/1078-0432.30706523","title":"Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas","display_name":"Supplementary Table 1 from Pharmacological Landscape of FDA-Approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas","publication_year":2025,"publication_date":"2025-11-25","ids":{"openalex":"https://openalex.org/W4416626621","doi":"https://doi.org/10.1158/1078-0432.30706523"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30706523","doi":"https://doi.org/10.1158/1078-0432.30706523","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706523","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.30706523","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063504569","display_name":"Gerhard Jungwirth","orcid":"https://orcid.org/0000-0001-7571-8947","observed_orcids":["https://orcid.org/0000-0001-7571-8947"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerhard Jungwirth","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7571-8947","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100401957","display_name":"Tao Yu","orcid":"https://orcid.org/0000-0001-7471-4290","observed_orcids":["https://orcid.org/0000-0001-7471-4290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tao Yu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7471-4290","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100453121","display_name":"Fang Liu","orcid":"https://orcid.org/0000-0003-2881-8114","observed_orcids":["https://orcid.org/0000-0003-2881-8114"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fang Liu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2881-8114","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055005604","display_name":"Junguo Cao","orcid":"https://orcid.org/0000-0002-2254-8152","observed_orcids":["https://orcid.org/0000-0002-2254-8152"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Junguo Cao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2254-8152","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068781838","display_name":"Montadar Alaa Eddine","orcid":"https://orcid.org/0000-0001-5994-993X","observed_orcids":["https://orcid.org/0000-0001-5994-993X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Montadar Alaa Eddine","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5994-993X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085166299","display_name":"Mahmoud Moustafa","orcid":"https://orcid.org/0000-0002-9146-0808","observed_orcids":["https://orcid.org/0000-0002-9146-0808"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mahmoud Moustafa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9146-0808","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075116222","display_name":"Amir Abdollahi","orcid":"https://orcid.org/0000-0002-8016-5897","observed_orcids":["https://orcid.org/0000-0002-8016-5897"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amir Abdollahi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8016-5897","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014216255","display_name":"Rolf Warta","orcid":"https://orcid.org/0000-0003-2821-4361","observed_orcids":["https://orcid.org/0000-0003-2821-4361"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rolf Warta","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2821-4361","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014073957","display_name":"Andreas Wilhelm Unterberg","orcid":"https://orcid.org/0000-0003-3742-3288","observed_orcids":["https://orcid.org/0000-0003-3742-3288"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andreas Unterberg","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3742-3288","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5025477516","display_name":"Christel C. Herold\u2010Mende","orcid":"https://orcid.org/0000-0002-1915-745X","observed_orcids":["https://orcid.org/0000-0002-1915-745X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christel Herold-Mende","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1915-745X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11251","display_name":"Meningioma and schwannoma management","score":0.9009000062942505,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11251","display_name":"Meningioma and schwannoma management","score":0.9009000062942505,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.016300000250339508,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aggressive-meningioma","display_name":"aggressive meningioma","score":0.8429999947547913},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.7649999856948853},{"id":"https://openalex.org/keywords/drug-sensitivity","display_name":"drug sensitivity","score":0.6370000243186951},{"id":"https://openalex.org/keywords/ixabepilone","display_name":"ixabepilone","score":0.9139999747276306},{"id":"https://openalex.org/keywords/romidepsin","display_name":"romidepsin","score":1.0},{"id":"https://openalex.org/keywords/omacetaxine","display_name":"omacetaxine","score":0.8899999856948853},{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/fda-approved-drugs","display_name":"FDA-approved drugs","score":0.8220000267028809},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.7160000205039978},{"id":"https://openalex.org/keywords/drug-screening","display_name":"drug screening","score":0.4959999918937683}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.7879999876022339},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.765999972820282},{"id":"https://openalex.org/C45235069","wikidata":"https://www.wikidata.org/wiki/Q278425","display_name":"Table (database)","level":2,"score":0.49880000948905945},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4002000093460083},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3522000014781952},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3508000075817108},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3495999872684479},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3246000111103058},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2793000042438507},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2612999975681305},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.258899986743927},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2547000050544739},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.25189998745918274}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.30706523","doi":"https://doi.org/10.1158/1078-0432.30706523","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706523","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30706523","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Table_1_from_Pharmacological_Landscape_of_FDA-Approved_Anticancer_Drugs_Reveals_Sensitivities_to_Ixabepilone_Romidepsin_Omacetaxine_and_Carfilzomib_in_Aggressive_Meningiomas/30706523","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30706523","doi":"https://doi.org/10.1158/1078-0432.30706523","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30706523","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9789000153541565,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4307208518","https://openalex.org/W4361950516","https://openalex.org/W2983204265","https://openalex.org/W4240421015","https://openalex.org/W2921990614","https://openalex.org/W4404237131","https://openalex.org/W4403352180","https://openalex.org/W4214818654","https://openalex.org/W4388588478","https://openalex.org/W4404237052"],"abstract_inverted_index":{"Drug":[0],"Screening":[1],"Data":[2]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-11-25T00:00:00"}